Cytowanie według stylu APA (wyd. 7)

(16384177), T. P. D., (16384180), K. W. E., (15107821), M. G. R., (16384183), M. Z., (16384186), Y. Q. R., (16384189), X. Z., . . . (10258780), F. M. (2025). Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.

Cytowanie według stylu Chicago (wyd. 17)

(16384177), Timothy P. DiPeri, et al. Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. 2025.

Cytowanie według stylu MLA (wyd. 9)

(16384177), Timothy P. DiPeri, et al. Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. 2025.